Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of 13-valent pneumococcal conjugate vaccine in healthy UK infants
2005-005130-12Phase 3Completed
- Sponsor
- Wyeth
- Start
- Apr 2006
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pneumococcal 13-valent conjugate vaccine in pneumococcal disease (2 arms), sponsored by Wyeth. Primary endpoints: Noninferiority of immune response to concomitant NeisVac-C or Pediacel after infant series, Meningococcal C immune response by serum bactericidal assay and 2 more. Started Apr 2006; status: completed.
02
Drugs
pneumococcal 13-valent conjugate vaccine
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on 2005-005130-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005130-12.